Desk›Healthcare› Shilpa Medicare Ltd
Shilpa Medicare Ltd
BSE 530549 · NSE SHILPAMED · ISIN INE790G01031 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹900.10
+4.65%
BSE close, 28 August 2026
₹17,604.32 cr
19.6 cr shares · Small cap
₹10,486.19 cr
as published
96.4× · 6.54×
EPS ₹9.34 · BV ₹137.63
597.03 / 132.97
₹ cr, as filed
23
6 selected · 26%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -1.5% |
|---|---|
| Against 52-week low | +246.2% |
| Day change | +4.65% |
| Size band | Small cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹9.34 |
|---|---|
| Price / earnings | 96.37× |
| Price / book | 6.54× |
| Book value — derived, price ÷ P/B | ₹137.63 |
| Return on equity | 6.79% |
| Operating margin | 36.54% |
| Net margin | 34.34% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 6.79%
- ROE as published
- 6.79%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 189.04 | 64.92 | 3.32 | 36.54% | 34.34% |
| Mar-26 · Q | 201.11 | 70.97 | 3.63 | 47.26% | 35.29% |
| FY25-26 | 597.03 | 132.97 | 6.80 | 35.72% | 22.27% |
Quarter on quarter
- Revenue, quarter on quarter
- -6.0%
- Net profit, quarter on quarter
- -8.5%
- Operating margin, quarter on quarter
- -1,072 bps
Disclosure profile 23 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Change in Management | 1 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| Press Release | 1 |
| Results | 1 |
| Selected sub-total | 6 |
| Procedural | |
| General | 5 |
| Analyst / Investor Meet | 3 |
| AGM / EGM | 2 |
| Annual Report | 1 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| Corporate Action | 1 |
| Newspaper Publication | 1 |
| Record Date | 1 |
| Trading Window | 1 |
| Procedural sub-total | 17 |
| Total | 23 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
23 filings · 6 selected · busiest 2026-08-05
Filing rhythm · the twelve most recent
2026-08-142026-10-07
SelectedProcedural
Filings
23 in the window · 12 earlier on record
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
25 September 2026 ·
Closure of Trading Window
Intimation of Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
23 September 2026 ·
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Assignment Of ESG Rating By CRISIL ESG Ratings.
Assignment of ESG Ratings by CRISIL ESG Ratings
Company Update / General View filing →
-
22 September 2026 ·
Analyst / Investor Meet - Intimation
Investors/Analysts meet
Company Update / Analyst / Investor Meet View filing →
-
18 September 2026 ·
USFDA Inspection Of Shilpa Medicare Limited, Unit VII, Analytical Services Division, Hyderabad.
USFDA Inspection of Shilpa Medicare Limited at Unit VII, Analytical Services Division, Hyderabad.
Company Update / General View filing →
-
11 September 2026 ·
Press Release / Media Release
Shilpa Medicare's Novel Complex Injectable OERIS (Ondansetron Extended - Release Injection, 100 mg/mL) receives final approval from Subject Expert Committee (SEC) for grant of marketing ....
Company Update / Press Release / Media Release View filing →
-
11 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 39th Annual General Meeting.
AGM/EGM / AGM View filing →
-
10 September 2026 ·
Initiation Of NCLT Order On FTF Pharma Private Limited, A Wholly Owned Subsidiary Of Shilpa Medicare Limited.
Initiation of NCLT Order on FTF Pharma Private Limited, a Wholly Owned Subsidiary of Shilpa Medicare Limited.
Company Update / General View filing →
-
19 August 2026 ·
Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company/Registrar & Transfer Agent /Depository Participants
Dispatch of letter to shareholders whose e-mail addresses are not registered with Company/ Registrar & Transfer Agent/ Depository Participants.
Company Update / General View filing →
-
18 August 2026 ·
Response On The News Item Captioned 'Shilpa Medicare Recalls Over 27K Vials Of Chemotherapy Drug In US' Published In The Online Edition Of The Economic Times On August 17, 2026 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Disclosure under Reg.30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Company Update / General View filing →
-
17 August 2026 ·
-
14 August 2026 ·
-
13 August 2026 ·
Reg. 34 (1) Annual Report.
Annual Report of Shilpa Medicare Limited for the FY 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
13 August 2026 ·
-
10 August 2026 ·
Earnings Call Transcript
Q1FY27 earnings conference call transcript
Company Update / Earnings Call Transcript View filing →
-
5 August 2026 ·
Analyst / Investor Meet - Outcome
Audio link of the Investor Conference call for Q1 FY27
Company Update / Analyst / Investor Meet View filing →
-
5 August 2026 ·
Investor Presentation
Investor Presentation for Q1FY27
Company Update / Investor Presentation View filing →
-
5 August 2026 ·
Final Dividend For The FY 2025-26
The record date for determining the shareholders entitled for payment of final dividend for FY 2025-26, if declared at the 39th AGM is Friday, 4th September 2026.
Corp. Action / Record Date View filing →
-
5 August 2026 ·
Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30 June 2026
Unaudited standalone and consolidated Financial Results for the Quarter ended 30 June 2026
Result / Financial Results View filing →
-
5 August 2026 ·
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended 30 June, 2026
Unaudited Financial Results for the Quarter ended 30 June 2026
Board Meeting / Outcome of Board Meeting View filing →
-
3 August 2026 ·
Change in Management
Appointment of Dr. Uday N. Harle as Chief Executive Officer of Shilpa Biologicals Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited w.e.f 03 August 2026. (Senior Managerial ....
Company Update / Change in Management View filing →
-
29 July 2026 ·
Analyst / Investor Meet - Intimation
Investor conference call for Q1-FY27 is scheduled to be held on 05 August 2026
Company Update / Analyst / Investor Meet View filing →
-
29 July 2026 ·
Board Meeting Intimation for Quarterly Financial Results
Shilpa Medicare Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Unaudited financial results ....
Board Meeting / Board Meeting View filing →
RSS feed for Shilpa Medicare Ltd · the 50 most recent filings